This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Using light pulses as a model for electrical defibrillation, scientists developed a method to assess and modulate the heart function. The research team has thus paved the way for an efficient and direct treatment for cardiac arrhythmias. This may be an alternative for the strong and painful electrical shocks currently used.
Biomedical engineers set the foundation for a ground-breaking treatment regimen for treating ventricular arrhythmia. Such innovation in painless defibrillation and preventing arrhythmia could revolutionize cardiac rhythm management. The study demonstrates the design and feasibility of a new hydrogel-based pacing modality.
Primary endpoint was the incidence of patients with new onset supraventricular arrhythmia (AF, atrial flutter or any supraventricular tachycardia) lasting >30s, post PFO closure.ResultsA total of 59 patients met the inclusion criteria. A total of 88 supraventricular arrhythmia events (96.6% days (IQR 1321). days (IQR 1321).
Introduction Wearable cardioverter-defibrillators (WCD) have emerged as a valuable tool in the management of patients at risk for life-threatening arrhythmias. These devices offer a non-invasive and temporary solution, providing continuous monitoring and the potential for prompt defibrillation when needed.
The targeted Automated External Defibrillator (AED) program in the Sao Paulo Metro has yielded promising results in improving survival rates for individuals experiencing out-of-hospital cardiac arrest (OHCA) due to ventricular arrhythmias. Circulation, Volume 150, Issue Suppl_1 , Page ASu505-ASu505, November 12, 2024.
Here is the transcript of the video: Implantable defibrillator is an important life saving device. It can automatically detect life threatening ventricular arrhythmias and treat them, either with a shock or, sometimes by overdrive pacing. These are high voltage, defibrillator shock coils. So, this is how an ICD works.
Automated external defibrillators (AEDs) and implantable cardioverter defibrillators (ICDs) are used to treat life-threatening arrhythmias. AEDs and ICDs use shock advice algorithms to classify ECG tracings as shockable or non-shockable rhythms in clinical practice.
Using an automated external defibrillator (AED) can help restore the heart’s rhythm until emergency medical personnel arrive. Use an automated external defibrillator (AED) if available. Without immediate intervention, sudden cardiac death can occur within minutes. Call for emergency medical assistance immediately.
Protection against the increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias is offered by the implantation of cardiac defibrillators. This is a single-centre retrospective study on the outcomes of all patients who had a transvenous defibrillator implant in 2015. Data from 235 patients were analysed.
The impact of supraventricular arrhythmias on the outcomes of guideline-compliance implantable cardioverter defibrillators programming. A greater magnitude of reduced ICD therapy was found in those with supraventricular arrhythmias.
Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist.
As it provides stable R-wave sensing, LBBP has been recently utilized to provide sensing of ventricular arrhythmia in patients receiving implantable cardioverter defibrillator(ICD) with CRT
However, he suddenly developed a series of malignant ventricular arrhythmias. He required multiple defibrillations within a period of a few hours. Below are printouts of some of the arrhythmias recorded. This time, the arrhythmia did not spontaneously terminate — but rather degenerated to VFib, requiring defibrillation.
Risk scores designed to predict adverse events (AE) including sudden death and ventricular arrhythmias can guide heightened surveillance and defibrillator (ICD) implantation. Variability in risk stratification derived from differing scores and guidelines has not been examined in repaired tetralogy of Fallot (rTOF).
2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Trial, reinforcing the performance and safety of the EV-ICD system. tim.hodson Thu, 09/05/2024 - 16:02 Sept.
However, ventricular arrhythmias (VA) are common, are mostly secondary to underlying myocardial scar, and have a higher incidence in patients with pre-LVAD VA.
Identifying patients with high-risk heart failure (HF) who would benefit from an implantable cardioverter-defibrillator (ICD) remains controversial. The molecular basis of the fQRS-arrhythmia-fibrosis connection in HF also needs to be explored. A potential marker for arrhythmic sudden death is fragmented QRS (fQRS).
The Extravascular Implantable Cardioverter Defibrillator (EV ICD) has demonstrated to be efficacious in the treatment of ventricular arrhythmias. Predicators of lead rotation have yet to be elucidated. The management of patients affected by lead rotation is of clinical significance and not yet described.
Implantable cardioverter-defibrillators (ICDs) are established as the standard of care for patients who are deemed at increased risk of life-threatening ventricular arrhythmias. Device-specific fears and symptoms of anxiety are the most common psychological sequelae experienced by ICD patients.1
Despite the implantable cardioverter defibrillator’s (ICD) effectiveness in saving patients with life-threatening ventricular arrhythmias (VAs), the temporal occurrence of VA following ICD implantation is unpredictable.
The wearable cardioverter defibrillator (WCD) is becoming a more and more widely used instrument for the prevention of sudden cardiac death of patients either with a secondary prevention implantable cardioverter defibrillator indication or with a transient high risk of sudden cardiac death.
Wearable cardioverter-defibrillator (WCD) is an alternative option for the prevention of sudden cardiac death in patients at high risk for malignant ventricular arrhythmias.
Ventricular arrhythmias and heart failure are common presentations of cardiac sarcoidosis (CS). Guidelines support implantable cardioverter-defibrillator (ICD) for many CS patients with reduced ejection fraction, but arrhythmic outcomes are poorly understood.
Implantable cardioverter defibrillators (ICD) are effective at terminating ventricular arrhythmias (VA), though have significant drawbacks. The opportunity to predict the onset of arrhythmia holds promise for insight into VA initiation and the opportunity to deliver therapy prior to an event.
Less is known about the relationship between NAFLD, ventricular arrhythmias (VAs), and cardiovascular events. Patients with nonalcoholic fatty liver disease (NAFLD) are at risk for cardiovascular diseases.
The feasibility and safety of utilizing LBBAP lead to provide sensing of ventricular arrhythmia in patients receiving implantable cardioverter defibrillator(ICD) with CRT has been demonstrated recently
He was defibrillated into VT. He then underwent dual sequential defibrillation into asystole. See these related cases: Cardiac arrest, defibrillated, diffuse ST depression and ST Elevation in aVR. This patient was witnessed by bystanders to collapse. They started CPR. EMS arrived and found him in Ventricular Fibrillation (VF).
For the past four decades, implantable cardioverter defibrillator (ICD) therapy has become the standard of care for preventing sudden cardiac death in high-risk individuals. The rate of ICD implantation has risen due to the increasing population age and the growing prevalence of cardiac arrhythmias.
This 1997 figure is the first conclusive evidence that the implantable cardioverter-defibrillator (ICD) reduces overall mortality compared with drugs in patients with life-threatening ventricular arrhythmias (from The New England Journal of Medicine, reprinted with permission from Massachusetts Medical Society).1
Arg14del) variant carriers are at risk of developing malignant ventricular arrhythmias (MVA). Accurate risk stratification allows for timely implantation of intracardiac defibrillators (ICD) and is currently performed using a multimodality prediction model. Phospholamban (PLN) p.(Arg14del)
During AHF, there is an increased risk of destabilizing the functional substrate and modulatory adding to the risk of ventricular arrhythmias (VAs) already created by the structural substrate. Scientific guidelines provide clear recommendations for the management of arrhythmias in chronic heart failure patients.
Automated external defibrillators (AEDs) have evolved as ‘game changers’ in the treatment of haemodynamically unstable ventricular arrhythmias as they can be used by virtually untrained members of the public. The usage of AEDs, however, can be improved as they are only employed in <20% of resuscitations.
Consequent implantable cardioverter-defibrillator (ICD) shocks can tremendously affect quality of life. Stereotactic arrhythmia radioablation (STAR) seems to reduce the number of ICD/external shocks, although most studies on STAR published to date only report results up to 12 months.
It cannot be treated with a defibrillator and often leads to death. Ventricular fibrillation is a type of irregular heartbeat that can cause the heart to stop beating, but an electric shock from a defibrillator can trigger the beating again.
Abstract The subcutaneous implantable cardioverter defibrillator (S-ICD) was developed as an alternative to the traditional transvenous implantable cardioverter defibrillator (TV-ICD), aiming to provide easier implantation, simplified detection algorithm of malignant ventricular arrhythmias and prevention from placing components in the cardiovascular (..)
The most common arrhythmia, atrial fibrillation , will affect approximately 12.1 Pacemakers and implantable cardioverter defibrillators (ICDs) are the standard of care to regulate a patient’s irregular heartbeat. million people in the United States by 2030, based on an estimation from the Centers for Disease Control and Prevention.
Progressive decline across periods in mortality rates among patients with implantable cardioverter-defibrillator (ICD). Abstract Introduction Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern.
What is the most likely cause of this arrhythmia? Despite prolonged resuscitation with multiple defibrillation attempts — the patient could not be saved. = He developed cardiac arrest shortly after the ECG in Figure-1 was recorded. QUESTIONS: How would YOU interpret the ECG in Figure-1 ? Figure-1: The initial ECG in today's case. (
BackgroundScreening for atrial fibrillation (AF) may reveal incidental arrhythmias of relevance. We furthermore report treatment decisions because of incidental arrhythmias. We found incidental arrhythmias in 94 patients (11.8%). Journal of the American Heart Association, Ahead of Print. of our cohort patients.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Over the past decades, hypertrophic cardiomyopathy has become a contemporary treatable disease.
ABSTRACT Aim To evaluate the predictive value of preoperative echocardiographic parameters for occurrence of VAs in patients with preexisting ICD undergoing LVAD implantation. Methods and Results All consecutive patients ( n =264) with previous ICD who underwent LVAD surgery between May 2011 and December 2019 at our institution were included.
We conducted this systematic review and meta-analysis to evaluate safety outcomes including risk of ventricular arrhythmias, new onset atrial fibrillation, Implantable Cardiac defibrillators (ICD) shocks, QRS duration reduction, heart failure hospitalizations and mortality.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content